HYDAMTIQ is a PARP-1/2 inhibitor (IC50: 29–38 nM) with anticancer, anti-inflammatory, and ischemia-protective effects; it inhibits lung PARP activity, effectively counteracts allergen-induced cough and dyspnea, and suppresses bronchial hyperresponsiveness to methacholine; it exhibits broad-spectrum antitumor activity against ovarian, breast, prostate, and pancreatic cancers, as well as glioblastoma multiforme; its in vivo efficacy has been demonstrated in animal models of cerebral ischemia, asthma, and cancer.